Skip to content

Alumis Inc. ALMS Operating margin

Operating margin at other companies

Amgen logo
AmgenAMGN
28.4%+6.6pp
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
-35,688.5%-39,114pp
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-4,558.4%-9,354pp
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-192.4%-205pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-697.7%+635pp
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
-39,428.9%-49,795pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on trailing twelve months.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s operating margin?
Alumis Inc. (ALMS) reported operating margin of -5,364% in Q1 2026.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.